PolymarketGeslotenBeschikbaarheid controlerenGeen KYC2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdDeze markt is beslist: No
Afgewikkeld: 11 jun 2026, 09:52
Door provider geverifieerde afwikkeling
CoinRithm heeft provider-onderbouwd bewijs voor de winnaar en afwikkelingstijd van deze markt.
Winnende Uitkomst
No
Op 7 dagen afstand
—
Op 24 uur afstand
8%
VerrassingHuidige impliciete kans
Nee 100%+0.9pt
Marktkwaliteit
22 / 100
Lage kwaliteit24u volume
€ 799,3
Liquiditeit
—
Liquiditeit onbekendBied / Laat
- / 0.4%
Marktdata
Bijgewerkt 70 dagen geleden
Verouderd4 jun 26, 19:3510 jun 26, 0:00
Waarschijnlijkheidstijdlijn
Yes0%
No100%
100%
0%
Regels
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
